Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

The somatic DDX41 hot spot mutation (p.R525H) causes skewed differentiation into plasmacytoid dendritic cells in human iPSC and leukemia models

Junichiro Kida, Maggie Fricker, Emily Stepanchick, Yael Kusne, Talha Badar, Terra Lasho, Mrinal Patnaik, Timothy Chlon

Blood (2025) 146 (Supplement 1): 678.

https://doi.org/10.1182/blood-2025-678

Published: 2025

Journal Articles

Insights into clonal and CBC changes at disease evolution among ccus patients

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, David Viswanatha, James Foran, Talha Badar, Cecilia Arana Yi, Yael Kusne, Antoine Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, William Hogan, Abhishek Mangaonkar, Mithun Shah, Hassan Alkhateeb, Mrinal Patnaik, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 5621.

https://doi.org/10.1182/blood-2025-5621

Published: 2025

Journal Articles

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Blood (2025) 146 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2025-5643

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

Ayalew Tefferi, Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Cecilia Arana Yi, Aasiya Matin, Hassan Alkhateeb, Talha Badar, Yassin Bashir, Kaaren Reichard, Rong He, Animesh Pardanani, Naseema Gangat

Blood (2025) 146 (Supplement 1): 3791.

https://doi.org/10.1182/blood-2025-3791

Published: 2025

Journal Articles

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Blood (2025) 146 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2025-1614

Published: 2025

Journal Articles

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Blood (2025) 146 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2025-1602

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Blood (2025) 146 (Supplement 1): 3320.

https://doi.org/10.1182/blood-2025-3320

Published: 2025

Journal Articles

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

Blood (2025) 146 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2025-7370

Published: 2025

Journal Articles

CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients

Abiola Bolarinwa, Natasha Szuber, Janick Caron-L'Ecuyer, Aref Al-Kali, William Hogan, Mithun Shah, James Foran, Talha Badar, Kaaren Reichard, Rong He, Naseema Gangat, Cinthya Mendoza, Michelle Elliott, Animesh Pardanani, Ayalew Tefferi

Blood (2025) 146 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2025-2013

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Clinical outcomes in adult AML with KMT2A rearrangements: A comparative analysis with R/R KMT2Ar and NPM1-mutated AML from the Mayo Clinic

Mahmood Aldapt, Kin Fentie, Joseph Parker, Hemant Murthy, James Foran, Naseema Gangat, Mohamed Kharfan-Dabaja, Jennifer Jiang, Yao-Shan Fan, Aref Al-Kali, Antoine Saliba, Cecilia Arana Yi, Nathan Punwani, Lisa Sproat, Mark Litzow, Mrinal Patnaik, Talha Badar

Blood (2025) 146 (Supplement 1): 7030.

https://doi.org/10.1182/blood-2025-7030

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients

Talha Badar, Mahesh Kumar, Yael Kusne, Terra Lasho, James Foran, Hemant Murthy, Mohamed Kharfan-Dabaja, Timothy Chlon, Naseema Gangat, Hassan Alkhateeb, Abhishek Mangaonkar, Rong He, David Viswanatha, Jennifer Jiang, Yao-Shan Fan, Alejandro Ferrer, Mark Litzow, Aref Al-Kali, Mrinal Patnaik

Blood (2025) 146 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2025-1442

Published: 2025

Journal Articles

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Yu-Hung Wang, Kristian Gurashi, Chien-Chin Lin, Carmelo Gurnari, Hussein Awada, Adrian Mosquera, Manuel Perez Encinas, Donal McLornan, Andrius Zucenka, Talha Badar, Bor-Sheng Ko, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, Jaroslaw Maciejewski, Nick Telford, Kiran Batta, Daniel Wiseman

Blood (2025) 146 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2025-4347

Published: 2025

Journal Articles

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Blood (2025) 146 (Supplement 1): 874.

https://doi.org/10.1182/blood-2025-874

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

The somatic hotspot mutation of DDX41 (p.R525H) elicits dominant-negative effects upon non-truncating germline variants, explaining similar disease risk as truncating variants.

Julianna Fisher, Emily Stepanchick, Andrew Wilson, Junichiro Kida, Talha Badar, Terra Lasho, Yael Kusne, Mrinal Patnaik, Timothy Chlon

Blood (2025) 146 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2025-3221

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The somatic DDX41 hot spot mutation (p.R525H) causes skewed differentiation into plasmacytoid dendritic cells in human iPSC and leukemia models

Insights into clonal and CBC changes at disease evolution among ccus patients

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)

Causes of death in DDX41-mutated myeloid neoplasms: A retrospective study

CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Clinical outcomes in adult AML with KMT2A rearrangements: A comparative analysis with R/R KMT2Ar and NPM1-mutated AML from the Mayo Clinic

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients

Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

The somatic hotspot mutation of DDX41 (p.R525H) elicits dominant-negative effects upon non-truncating germline variants, explaining similar disease risk as truncating variants.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only